Evidence-Based Medicine Sliding Into Market Economy-Based Medicine
Modern medicine stands at a crossroads. What began as a noble framework — evidence-based medicine (EBM) — designed to ground clinical decisions in rigorous scientific data, has increasingly been co-opted by market forces. The result is a quiet but consequential transformation: from medicine guided by patient outcomes to medicine guided by pharmaceutical profit.
Shifting the Goalposts
A telling example emerged at the 2024 European Congress of Cardiology, where blood pressure diagnostic thresholds were lowered to align with American standards. While presented as a scientific update, many specialists openly questioned whether the true motive was expanding the market for antihypertensive medications. When diagnostic criteria shift in ways that dramatically increase the number of "patients," one must ask: who benefits most — the patient, or the industry?
This pattern is not new. The same logic appears in cholesterol management, where statins — once revolutionary — are now being quietly sidelined in anticipation of lipoprotein (a) inhibitors, a new and significantly more expensive drug class still in development. Artificially diminishing the perceived effectiveness of affordable, proven therapies to clear a path for costlier alternatives is not science. It is strategy.
Aspirin vs. Clopidogrel, Warfarin vs. Novel Anticoagulants
The debate over whether clopidogrel truly outperforms aspirin — despite costing far more — remains unresolved, yet prescribing trends have favored the expensive option. Similarly, emerging publications now question whether newer oral anticoagulants genuinely justify replacing warfarin, a drug that is cheap, well-understood, and monitored effectively. These are not fringe concerns. They reflect a broader pattern where clinical guidelines lag behind commercial interests rather than patient welfare.
The Polypharmacy Problem in H. pylori Therapy
Anti-Helicobacter therapy offers another cautionary tale. Instead of understanding the root causes and biological mechanisms behind H. pylori's persistence, medicine has responded by layering treatment upon treatment — creating increasingly complex, multi-drug regimens. This polypharmacy approach, considered malpractice in thoughtful modern therapeutics, burdens patients' bodies without guaranteeing eradication. It raises a fundamental question: are we treating the patient, or are we treating a market segment?
Rigged by Design
Perhaps the most structurally deceptive feature of market-driven EBM is how new drug trials are designed. Rather than comparing a new medication head-to-head against an existing one — the scientifically honest approach — trials frequently test new drugs as add-ons to existing regimens. This combinatorial design virtually guarantees a positive result, protects invested capital, and avoids the reputational and financial catastrophe of a failed study. The science is technically compliant; the intent is commercially motivated.
When Evidence Becomes Criminal
The American "stent scandal" illustrates the most dangerous endpoint of this trajectory. Cardiologists installed coronary stents in patients who did not require them, justified — astonishingly — under the umbrella of evidence-based medicine. These patients were unnecessarily exposed to procedural risks and placed on long-term anticoagulation therapy with its own serious side effects. Financial incentives to hospitals and physicians drove clinical decisions that should have been governed solely by patient need. That evidence-based medicine could be weaponized to justify such practices is not merely a failure of ethics — it is a structural indictment of a system without sufficient safeguards.
The Need for a Governing Principle
The slide from evidence-based medicine into market economy-based medicine is not inevitable — but it is predictable without a corrective framework. Introducing a guiding principle — one that prioritizes biological rationality and disease optimization over commercial expansion — could serve as a guardrail. If EBM's research agenda were bounded by such a principle, trials designed purely to protect financial investments would lose their legitimacy. The goal of medicine is to heal, not to generate revenue. Reclaiming that goal requires not just scientific rigor, but ethical architecture built into the foundations of how research is designed, funded, and applied.
You can learn more by reading our e-book or listening to our audiobook
Comments